Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up

Dahan, Karine; Debiec, Hanna; Plaisier, Emmanuelle; Cachanado, Marine; Rousseau, Alexandra; Wakselman, Laura; Michel, Pierre-Antoine; Mihout, Fabrice; Dussol, Bertrand; Matignon, Marie; Mousson, Christiane; Simon, Tabassome; Ronco, Pierre; behalf of the GEMRITUX Study Group, on

doi:10.1681/asn.2016040449

Public

Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up

Shared by NobleBlocks on Jun 27, 2016 • 12:00 AM UTC

Authors:

Karine Dahan

Hanna Debiec

Emmanuelle Plaisier

Abstract

Randomized trials of rituximab in primary membranous nephropathy (PMN) have not been conducted. We undertook a multicenter, randomized, controlled trial at 31 French hospitals (NCT01508468). Patients with biopsy-proven PMN and nephrotic syndrome after 6 months of nonimmunosuppressive antiproteinuric...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!